A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1) Meeting Abstract
| Authors: | Drilon, A. E.; Ou, S. H. I.; Cho, B. C.; Kim, D. W.; Lee, J.; Lin, J. J.; Zhu, V. W.; Kim, H.; Kim, T. M.; Ahn, M. J.; Camidge, D. R.; Lim, J. K. C.; Stopatschinskaja, S.; Cui, J. J.; Hyman, D. M.; Doebele, R. C.; Shaw, A. T. |
| Abstract Title: | A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1) |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 109s |
| Language: | English |
| ACCESSION: | WOS:000442916001293 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.2513 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2513 -- Source: Wos |
